Inside CellProthera's Strategic SEQENS Partnership: Scaling Cell Therapy from Lab to Commercial Reality

"There are not that many European CDMOs with commercial expertise in cell therapy - who understand the regulatory requirements and production challenges when you have to manufacture large quantities on a regular basis. This is why we ended up with a very short list of two or three potential suppliers."

CellProthera's recent announcement of its manufacturing partnership with SEQENS for Phase III trials marks a pivotal moment in the French biotech's journey from research lab to commercial reality. The eight-month technology transfer process now underway represents years of strategic planning and hard-won lessons about scaling cell therapy manufacturing.

In an exclusive interview, Matthieu De Kalbermatten, CEO of CellProthera, reveals the detailed selection process that led to choosing CELLforCURE by SEQENS as their manufacturing partner. His insights offer a rare glimpse into how biotechs navigate the complex transition from early development to commercial-scale production.

Read article